On one hand, slowing disease progression prior to the manifestation of pronounced cognitive loss and dementia is incomparably better for the patient than extending life at the dementia stage; on the other hand, the odds of success appear to be higher at disease stages where the extent and amount of neurofibrillary tau lesions is not insurmountable yet. Here, MAPT is linked to dementia.